Filling errors, counterfeit packs gain FDA's attention | Packaging World
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
FDA Warns Teva API Plant in China | RAPS
Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva confirms US FDA warning letter for Hangzhou, China API plant
Teva Recalls U.S.-Made Drugs Following Contamination Fears | 2021-10-04 | SupplyChainBrain
FDA Scorecard: Drug Shortages and Inspections - DCAT Value Chain Insights
Troubled Teva plant in Hungary faces an FDA crackdown - STAT
Teva Pharma Suspends Irvine Production After FDA Probe - Orange County Business Journal
FDA Warning Letter To Teva Highlights Need For Accurate Root Cause Investigations :: Pink Sheet
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Site Inspections | Teva api
Celltrion FDA warning causes headache for Teva's biologics ambition
Teva Recalls One Lot Of IDArubicin Hydrochloride Injection
FDA warning letter says Teva China plant has more work to do on API issues | Fierce Pharma
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva months from restarting production at Hungary plant banned by US FDA
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
After Ignoring Letters From US FDA, Teva And Cipla Will Have ANDAs Withdrawn :: Pink Sheet
